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1ABSTRACT
Model to Predict Treatment Response to Trastuzumab in HER2 Positive 
Metastatic Gastric Cancer Patients
Dongwoo Chae
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Kyung Soo Park)
Objectives
This study was carried out to build a comprehensive mathematical model to 
predict treatment outcome in HER2 positive metastatic gastric cancer patients.
Materials and Methods
Data were collected from 69 advanced gastric cancer patients who participated in a 
clinical study conducted in Severance hospital, Seoul, Korea, as part of ToGA 
clinical trial. Sum of longest diameter of target lesions was evaluated at each clinic 
visit based on RECIST criteria. A tumor growth inhibition (TGI) model was 
developed under a K-PD modeling framework. Parametric survival models were 
2subsequently built to link TGI model predictions to PFS and PPS. A separate dataset 
consisting of 86 patients was used for model validation.
Results
The tumor size predictions generated by the developed TGI model provided a good 
fit with the observed tumor sizes. HER2 3+ patients showed higher sensitivity to 
trastuzumab compared to HER2 1+/2+ patients. Higher WHO histologic grades 
were associated with faster tumor progression. Prior gastrectomy history and lower 
ECOG score were associated with lower hazard of non-measurable lesion PD. PFS 
and PPS showed positive correlation when WHO histologic grade were either I or II. 
Such correlation disappeared for WHO histologic grades of III and IV.
Conclusion
Based on the developed model, it is possible to generate individualized predictions 
of treatment response and patient survival. This will help optimize treatment in 
HER2 positive metastatic gastric cancer patients.
3Model to Predict Treatment Response to Trastuzumab in HER2 Positive 
Metastatic Gastric Cancer Patients
Dongwoo Chae
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Kyung Soo Park)
I. INTRODUCTION
In 2010, FDA granted approval for trastuzumab in combination with cisplatin and a 
fluoropyrimidine for the treatment of patients with HER2 overexpressing metastatic 
gastric or gastroesophageal (GE) junction adenocarcinoma. The approval was based 
on a significant improvement in median overall survival of 2.5 mos with 
trastuzumab plus chemotherapy treatment compared to chemotherapy alone 
demonstrated in the ToGA clinical trial.1 Subsequent research found that 
trastuzumab treatment prolonged survival of HER2 positive patients significantly 
more than HER2 negative patients. 2
Currently, a standardized dosing regimen of trastuzumab with initial loading dose of 
8 mg/kg followed by a maintenance dose of 6 mg/kg every 3 wks is used to treat all 
HER2 positive metastatic gastric cancer patients. Clearly, there is no consideration 
of factors such as tumor burden, histology, or HER2 status. In an era of personalized 
4medicine, unfavorable consequences of ignoring individual variability are being 
increasingly acknowledged.
To achieve optimal individualized therapy, one must first acquire individual 
predictions of treatment response. Precise predictions often need computerized
system built upon validated mathematical models.
Based on known physiology and landmark discoveries made in the past few 
decades,3-10 we have sought to build a physiological model of tumor size dynamics 
and rely on computer simulations to investigate the complex nature of treatment 
responses. 
Such an approach is gaining increasing popularity in recent years. There is now a 
rich library of published tumor growth inhibition (TGI) models proposed by 
numerous research groups. 11-15
The greatest benefit of using computational models to estimate dose-response 
relationship stems from its comprehensive nature. Once tumor size changes can be 
predicted, various endpoints can be automatically deduced. For example, 
intermediate endpoints such as early tumor shrinkage (ETS) and depth of response 
(DoR),16-22 can be easily deduced from the tumor size dynamics. Progressive disease 
(PD), as defined in RECIST 23 criteria, can also be predicted by calculating the time 
at which the predicted tumor size rises above 20% of the minimum.
In this work, we have successfully developed a tumor growth inhibition (TGI) 
model of metastatic gastric cancer patients and linked it with patient survival. Our 
model system would enable the clinicians to predict treatment responses in patients 
harboring different covariates.
Theoretical exposition on tumor growth and chemotherapy response will be given 
first. 
5II. MATERIALS AND METHODS
1. Theory development
A. Models of Tumor Growth and Progression
The fundamental property of any proliferating cell is the doubling time (DT), 
defined as the time needed for doubling of its volume. Specific growth rate 
(SGR; %/time) is defined as log(2)/DT.24
A general equation describing tumor growth is shown below:
  
  
=   ( ,  )  …    (1.1.1)
N denotes tumor size and   ( ,  ) specific growth rate.
(A) Density dependence
Due to scarcity of resources, tumor growth often slows down as tumor size gets 
larger. Logistic and Gompertz models are widely used to describe such behavior.
  ( ,  ) =   (1 −	
 
    
) (Logistic growth model)
  ( ,  ) =   log	(
    
 
) (Gompertz growth model)
Dependence of specific growth rate (  ) on N is defined as ‘density dependence’ of 
tumor growth.
6(B) Tumor progression
It is being increasingly recognized that genotypes (and phenotypes) of cancer cells 
in an individual are highly heterogeneous.25,26 Such heterogeneity is primarily 
generated through random mutations and is the driving force of clonal evolution.27
The following equation is known in evolutionary game theory as the ‘replicator 
equation’28.
   
  
= (  ( ) −	  ( ))   …    (1.1.2)
In the above,    is the proportion of type k in the population, x = (  , …,   ) is 
the vector of the distribution of types in the population,   ( ) is the fitness of type 
k, and   ( ) is the average population fitness. 
The fitness   ( ) in our work is defined as the specific growth rate of type k. 
  ( ) is then the average SGR of the population x.
Based on Eq. (1.1.2), the following can be derived.
   ( )
  
= ∑(  ( ) − 	  ( ))
   
…    (1.1.3)
Since the elements of the population vector x sum to unity by definition, the 
(R.H.S.) of Eq. (1.1.3) can be interpreted as the variance of   ( ) defined on the 
support vector x. This important conclusion is known as ‘Fisher’s fundamental 
theorem of natural selection’8.
7We will denote 
   ( )
  
(= ∑(  ( ) −	  ( ))
   ) as β in our work. As we shall 
see, β is one of the most important parameters of our model.
B. Models of Chemotherapy Response
(A) Dose-response curves
The log-kill hypothesis of chemotherapy (first established by Skipper and 
colleagues 29,30) in the 1960s found that in experimental tumors, cell-kill increased 
logarithmically with dose.
Denoting S as the surviving cell fraction,
S = exp(-kD) … (1.2.1)
(D: total dose, k: rate constant of cell kill)
Since total dose is proportional to AUC, Eq. (1.2.1) can also be expressed as:
S = exp(-kAUC) … (1.2.2)
For many cell cycle phase-specific drugs, cytotoxicity is not a simple function of 
AUC. Time of exposure may be more important than drug concentration, and 
plateaus in cytotoxicity are observed with increasing drug concentrations. Adams 31
proposed that appropriate weighting must incorporating into either concentration or 
time. That is, 
S=exp(-k∫     ) … (1.2.3)
8Larger n would result in more weight given to drug concentration. In the extreme 
case of n=0, drug concentration has no role to play and it is the exposure time alone 
that determines response.
In addition to drug response being a complex function of both drug exposure and 
treatment time, it was soon discovered that treatment response is often dependent on 
tumor size itself. 
In 1988, Norton fit a Gompertzian model to human breast cancer growth.32 Under 
the Gompertzian model, the tumor growth rate attenuates with tumor age and size, 
implying that smaller tumors are relatively more susceptible to chemotherapy. 
Using this as theoretical motivation, Norton and Simon proposed the “Norton-
Simon hypothesis”, which was stated as follows:
“Therapy results in a rate of regression in tumor volume that is proportional to the 
rate of growth that would be expected for an unperturbed tumor of that size.”
In mathematical terms, unperturbed tumor growth is described as follows:
  
  
=    	   
    
 
… (1.2.4)
In the presence of chemotherapy, Eq. (1.2.4) changes to:
  
  
= (   −	    ) 	   
    
 
… (1.2.5)
Here,      is a coefficient of drug efficacy. If log-kill hypothesis were true, the 
equation should have been:
  
  
=    	   
    
 
−	      … (1.2.6)
9It has been found in many cases that Eq. (1.2.5) is a closer description of reality 
than Eq. (1.2.6). From a mathematical perspective, log-kill hypothesis and Norton 
Simon hypothesis are corollaries of exponential and Gomperz-type growth models, 
respectively, associated with negative specific growth rates.
(B) K-PD model
It is often the case that plasma concentration information is absent. In these 
circumstances, a way to use dose information as a substitute has been proposed in 
the classic papers.33,34
The simplest approach is to use dose as a simple covariate. With this assumption, 
Eq. (1.2.3) becomes:
S=exp(-k∫        ) (1.2.7)
Problem with this approach is that dose is assumed to distribute evenly within each 
dosing interval. 
To mimic the entry and elimination of drug into and out of the biophase, a 
hypothetical compartment might be introduced. Jacqmin34 named this hypothetical 
compartment as ‘virtual’ compartment. Note that virtual compartment does not 
correspond to any real physiological entity. 
In the original formulation by Jacqmin, a single virtual compartment receives bolus 
input of the drug. The drug is eliminated from this virtual compartment at a rate 
proportional to the amount in the compartment (i.e. 1st order elimination). The 
author, however, states that the input profile for the virtual PK compartment can be 
more complex, including for example zero or first order input rates, if the PD data 
allows the identification of the extra input parameters 34.
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A K-PD model with a single delay compartment can be modeled as shown below:
  
  
= -KDE∙ C (delay compartment)
  
  
= KDE∙ (C − V) (virtual compartment)
After bolus input into compartment C, the drug is transferred to V with a rate 
constant KDE.
KDE∙V then acts as an exposure measure which is fed into one of the following 
functions:
Drug effect =      KDE∙V (Linear model)
Drug effect =     log(1 + KDE∙V) (Log-linear model)
Drug effect = 
       ∙ 
        ∙ 
(Ordinary Emax model)
Drug effect = 
    (   ∙ )
 
    
  (   ∙ ) 
(Sigmoid Emax model)
In our work, we have used the K-PD modeling framework to incorporate dose 
information of trastuzumab, cisplatin, and capecitabine/5-FU.
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C. Time to Event Models 
(A) Progression Free Survival and Overall Survival
Progression Free Survival (PFS) is the time to progressive disease (PD). 
According to the revised RECIST guideline (version 1.1)23, progressive disease (PD) 
can be diagnosed based on measurable lesions defined as the sum of longest 
diameters of target lesions or non-measurable lesions that include leptomeningeal 
disease, ascites, pleural or pericardial effusion, inflammatory breast disease, 
lymphangitic involvement of skin or lung, abdominal masses/abdominal 
organomegaly identified by physical exam that is not measurable by reproducible 
imaging techniques. Because of the contribution of non-measurable lesions, we 
need a separate model other than a tumor size prediction model to predict PD. 
Overall survival (OS) is the time to patient death.
Both PFS and OS are calculated relative to the reference time point of baseline 
assessment at the beginning of study. 
(B) Hazard functions
If in a unit time interval the hazard of an event is h, the number of events would be 
hN(t), where N(t) denotes the maximum number of events at a given time t.  
Survival S(t) is defined as N(t)/N(0). It is the ratio of maximum number of 
occurrence at time t to that at time 0. 
Since at each time the number of events is hN(t), the rate of change of N(t) is -hN(t). 
The negative sign denotes that once an event occurs for a certain individual, that 
individual is excluded from subsequent analysis. 
12
From
  ( )
  
= -hN(t), separating variables and integrating yields N(t) = N(0)exp(-
ht). Hence, survival S(t) = N(t)/N(0) = exp(-ht). Assuming constant hazard, survival
is simply an exponential function. Otherwise, h(t) is often assumed to follow a 
certain distribution. Commonly used probability distributions to describe time 
varying hazard are (1) Weibull, (2) Gompertz-Makeham, (3) gamma, (4) 
generalized gamma, (5) log-normal, (6) log-logistic, and many others.35
Weibull model assumes that hazard is propotional to a certain power of time.
h(t) = ℎ p    
When p = 1, the Weibull model reduces to a constant hazard model since 
dependence on time is eliminated. If p > 1, the hazard will increase monotonically 
with time. If 0 < p < 1, the hazard will decrease monotonically with time.
A similar model is Gompertz-Makeham model:
h(t) = exp(a + bt)
It is often the case that hazard function is hump-shaped (i.e. there is a time window 
of maximal hazard after which the hazard decreases again). Log-normal hazard 
model is simply a log-normal distribution having time as the independent variable. 
A log-logistic model is defined as shown below:
h(t) = 
       	
  (  ) 
Log-logistic hazard has a characteristic hump shape and is appropriate for modeling 
hazards that increases and then decreases.
13
(C) Covariate incorporation into the hazard function
The hazard function can be affected by different covariates. The most widely used 
method to incorporate covariates is a generalized linear model using a logarithmic 
transformation.
Log(h) =    +   	    + … +       
This is called a proportional (or multiplicative) hazard model.
Less often, hazard is formulated as a simple linear combination of the covariates.
h =    +   	    + … +       
This is called an additive hazard model. Unlike proportional hazard model, the 
absolute change in risk, instead of the risk ratio, is of primary interest. A recent 
article that used additive hazard regression model to analyze the natural history of 
human papillomavirus 36 should serve as a good reference.
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2. Data
A total of 69 advanced gastric cancer patients enrolled into ToGA phase III clinical 
trial who received either of the following regimens - Trastuzumab + XP/FP or 
XP/FP – as 1st line therapy, beginning from December 2005 in Severance hospital, 
Seoul, Korea, were used for model building. 
ToGA trial is a multi-centered trial to evaluate the efficacy of Trastuzumab in HER2 
overexpressing gastric and GEJ cancer patients. Patients whose gastric or GEJ 
tumors showed HER2 overexpression by IHC or gene amplification by FISH were 
eligible for the study. Patients were randomized in equal numbers to capecitabine 
1000 mg/  /day on days 1-14 followed by 1 week rest (or 5-FU 800 mg/  /day on 
days 1-5 continuous infusion), cisplatin 80 mg/  /day on day 1 every 3 weeks for 
six cycles or to capecitabine (or 5-FU), cisplatin and trastuzumab 8 mg/kg loading 
dose on day 1 followed by 6 mg/kg every 3 weeks.1 Trastuzumab was continued 
until progression of the disease.
In the published article 1, it was shown that OS was improved significantly with the 
addition of trastuzumab (13.8 mos in trastuzumab arm compared with 11.1 mos in 
the chemotherapy alone arm, p = 0.0046). Median PFS was 6.7 mos in the 
trastuzumab arm compared to 5.5 months in the chemotherapy alone arm (p = 
0.0002). The overall response rate was 47.3% versus 34.5% in trastuzumab plus 
chemotherapy and chemotherapy, respectively (p = 0.0017).
Post hoc exploratory analysis showed that trastuzumab and chemotherapy improved 
OS in patients with IHC 2+ and FISH positive or IHC 3+ patients compared with 
IHC 0 or 1+ and FISH-positive patients.
In our analysis dataset, RECIST evaluation was done at every clinic visit (which 
took place approximately every 3 wks) and maximum tumor diameter (mm) was 
15
recorded. Time of PD diagnosis and patient death were also recorded, and 
progression free survival and overall survival calculated. Extra information 
regarding the cause of PD (tumor growth > 20% relative to best response, 
appearance of new lesion, or clinical deterioration) was also given.
In addition to basic patient demographics, histologic grade, organs of metastases, 
and ECOG score were also recorded. The summary of analysis datasets is shown in 
Table 1.
Table 1. Patient demographics and covariates of training and test datasets
Characteristics Training dataset 
(n=69)
Test dataset 
(n=86)
P-value
Age [yrs] (median,  
range)
59 (33-80) 60 (36-82) 0.78†
Gender Male: 47
Female: 22
Male: 63
Female: 23
0.60‡‡
Weight [kg] (mean 
± sd)
59.06 ± 9.58 61.87 ± 10.32 0.081†
Baseline tumor size 
[mm]
(median, range)
73.60 (10.40-
429.00) 
42.25 (1.10-252.80) 0.0001††
Histologic grade
Well
Moderate
Poor
Signet ring cell
Mucinous
7 (10.14%)
40 (57.97%)
18 (26.09%)
4 (5.80%)
0 (0.00%)
5 (5.68%)
42(47.72%)
36 (40.91%)
4(4.55%)
1 (1.14%)
0.14‡
HER2 receptor status
16
Negative
Positive
5 (7.25%)
64 (92.75%)
19 (22.09%)
67 (77.91%)
0.021‡‡
ECOG score
0
1
2-3
32 (46.38%)
29 (42.03%)
8 (11.59%)
54 (62.79%)
27 (31.40%)
5 (5.81%)
0.12‡
Previous 
gastrectomy 
52 (75.36%) 26 (30.23%) <0.0001‡‡
Metastatic status
Liver
Peritoneum
Distant lymph nodes
Ovary
Brain
Lung
Bone
32 (25.81%)
22 (17.74%)
50 (40.32%)
5 (4.03%)
0 (0.00%)
9 (7.26%)
6 (4.84%)
44 (25.88%)
37 (21.76%)
57 (33.53%)
3 (1.76%)
1 (0.59%)
21 (12.35%)
7 (4.12%)
0.49‡
Lauren classification
Intestinal
Diffuse
Mixed
Unknown
15 (21.74%)
3 (4.35%)
1 (1.45%)
50 (72.46%)
17 (19.77%)
5 (5.81%)
1 (1.16%)
63 (73.26%)
0.96‡
Progression free 
survival [days]
(median, range)
218 (14-1440) 215 (30-1987) 0.56†
Overall survival 
[days]
(median, range)
428 (76-2423) 254 (30-1987) 0.16†
17
The raw data plots of tumor size vs. time and survival are shown in Figure 1 and 2, 
respectively.
Figure 1. Maximum Tumor Diameter [mm] vs. Time [months].
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Figure 2. Kaplan Meier Curves of Progression Free (left) and Overall (right) 
Survival.
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3. Exploratory Data Analysis
Definitions.
- Early tumor shrinkage (ETS): A reduction of at least 20% in tumor size at 
first reassessment
- Depth of response (DoR): The maximal tumor shrinkage observed in a 
patient
- Early shrinkage rate (Ksh): Relative reduction in tumor size at first 
reassessment calculated as [log (tumor size at first visit) – log (baseline 
tumor size)]/visit interval
Scatterplots were generated to spot possible correlations among the above variables. 
Regression analysis was performed to characterize the correlation quantitatively. 
Simple linear regression analyses of log(PFS) were done to search for covariates 
affecting PFS. Semi-parametric Cox-PH analyses were then performed to assess 
factors affecting relative risks of PD events.
Baseline tumor size was regressed against other patient covariates to check for 
factors that positively correlate with it. This will be useful in cases where we do not 
have baseline tumor size measurement.
Finally, effect of trastuzumab treatment was assessed by calculating depth of 
response and median (and mean) PFS in treatment and non-treatment groups and 
was stratified by HER2 receptor status.
Analyses were performed using Python 2.7 and R.
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4. MODELS
All model parameters were estimated using NONMEM software version 7.3. R 
(RStudio) and Python 2.7 were used for additional data exploration, analysis, and 
simulations.
A. Tumor Size Model
Two types of cancer cells – those sensitive to at least one of the drugs used and 
those resistant to all drugs – were assumed in our model. In line with Norton-Simon 
hypothesis,6 specific growth rate (SGR) was assumed to decrease with increasing 
tumor size.37,38 Logistic growth model was used to capture this property. 
In addition, increase of SGR with time was assumed to occur at a rate of β. 
  (t) =   (0) + β ∙ t - Eff (2.1.1)
Chemotherapy was assumed to trigger cell death with a time delay governed by the 
equilibrium rate constant of the virtual compartment. Since all patients were treated 
with cisplatin and 5-FU/capecitabine, there was no placebo group to estimate 
efficacies of these drugs. Hence, drug effects of these agents were lumped under an 
umbrella term of ‘cytotoxic drug effect’ that was assumed as being proportional to 
the sum of log(exposure) of each drug. 
Cytotoxic drug effect =     ,  ∙ {log(         ) + log(5 −   )} (2.1.2)
Since placebo group does exist for trastuzumab, its efficacy was separately 
estimated as a model parameter. There is evidence that trastuzumab and cisplatin 
show synergistic effects.39 Hence, it must be understood that the term ‘trastuzumab 
drug effect’ is a drug effect of trastuzumab conditioned on concurrent chemotherapy 
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of cisplatin.
Trastuzumab drug effect =     ,  ∙ log	(           ) (2.1.3)
In drug resistant tumor cells, Eff = 0, in which case the following is true.
  (t) =   (0) + β ∙ t (2.1.4)
Henceforth, we will denote   (t) of sensitive and resistant tumor cells as   , (t) 
and   , (t), respectively. 
The parameter   (0) is generally difficult to estimate since pre-treatment tumor 
sizes (based on RECIST evaluation) are often unavailable. The only pre-treatment 
information given is the baseline tumor size N(0). Since higher   (0) would have 
given rise to higher N(0), a plausible guess would be that    (0) is roughly 
proportional to log(N(0)). Hence, the following linear model was used to estimate 
  (0).
  (0) =   (0)_intercept +   (0)_slope∙log(N(0))
KPD model 34 was used to describe the time course of drug exposure.
  =̇ δ -     ∙   (2.1.5)
 ̇ =     ∙   -     ∙   (2.1.6)
In the above equation, E represents hypothetical drug amount in the effect site. A 
first-order elimination of E was assumed. δ stands for dirac delta function that 
represents drug input given as a bolus. Percent standard doses of trastuzumab, 
cisplatin, and capecitabine were used as input doses.
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Denoting sensitive and resistant tumor cells as S and R, their rate of change can be 
described as:
  =̇   ,  ∙S∙(1 -
 
    
) (2.1.7)
 ̇ =   ,  ∙R∙(1 -
 
    
) (2.1.8)
N = S + R (2.1.9)
S(0) = Fr∙N(0) (2.1.10)
R(0) = (1 – Fr)	∙N(0) (2.1.11)
N represents total tumor size and      maximum tumor size.
N(0), S(0), and R(0) represent the initial size of total, sensitive, and resistant tumor 
cells. Fr is a parameter that represents the fraction of N(0) that is sensitive to 
cytotoxic effects. In the actual modeling, Fr has been subdivided into 7 fractions, 
each representing a specific combination of chemotherapeutic regimen (=3C1 + 3C2
+ 3C3).
To estimate Fr, we have introduced two parameters P and Q. P represents the 
probability of resistance to cytotoxic agents (cisplatin and 5-FU/capecitabiine). Q 
represents the probability of resistance to trastuzumab. P and Q were assumed 
independent of each other.
To constrain P and Q within the interval of [0, 1], separate parameters ζ and κ
were introduced such that P = 
 
  	 
and Q = 
κ
  	κ
.
Fr was then calculated as follows:
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Fr =   (1 – Q) + 2(1-P)PQ + 2P(1-P)(1-Q) + (1 −  ) (1 – Q)
In Eq. (2.1.7) and (2.1.8),      was assumed to be proportional to Log(N(t=0)) to 
reflect the characteristics of nutrient-limited tumor growth.40 The density 
dependence term (1 -
 
    
) reflects the assumption proposed by Norton-Simon 
hypothesis.10
The schematic diagram describing the final tumor size model is shown in Figure 3.
Figure 3. Diagram of treatment response model.
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The meaning of the model parameters are explained based on a typical tumor 
growth curve. (See Figure 4)
1) The initial slope of tumor shrinkage is closely represented by   (0) -     . 
2) Depth of response (DoR) is maximum percentage tumor shrinkage.41 Based 
on our model, DoR is strongly determined by total fraction of sensitive 
clones,     , and β. 
3) Length of stable disease (SD) – defined as a state of neither sufficient 
shrinkage to qualify for PR nor sufficient increase to qualify for PD 42 –
depends on the magnitude of β. If β = 0, no resistance would develop and 
tumor size would reach an asymptote. 
4) The slope of the regrowth phase is primarily determined by β.
Figure 4. A typical tumor curve under treatment.
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B. Covariate Model
Candidate covariates are demographic factors (such as age, weight, and gender) and 
clinical characteristics such as ECOG score, WHO histologic grade, HER2 receptor 
positivity, location of primary tumor, and types and number of metastatic organs.
Covariate search was done based on clinically known or suspected relationships and 
EBEs vs. covariate plots. Candidate covariates were then tested using stepwise 
covariate model building.43
C. Survival Model
(A) PFS prediction model
Two versions of PFS, which we denote as PFS1 and PFS2, were estimated.
PFS1 was simply calculated from the tumor size model because the model yields 
the full growth curve. For PFS2, a separate time-to-event model to predict PD based 
on non-measurable lesion was constructed. Henceforth, we will denote the model 
used for generating PFS1 and PFS2 as Model 1 and 2, respectively.
PFS prediction was obtained by selecting the smaller of the two estimates as below. 
PFS = min(    ,     )
A probability distribution of patient dropouts was also estimated and was used to 
generate censored events. Different parametric distributions – exponential, Weibull, 
log-logistic, and Gompertz – were fitted to time-to-event data.
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(B) PPS prediction model
Post-progression survival (PPS) is defined as the difference of overall survival (OS) 
and progression free survival (PFS). PPS should depend partly on the clinical 
outcome of first-line chemotherapy, but also on subsequent treatment. 
Cox-proportional hazards regression 44,45 was conducted to assess the significance of 
the candidate covariates. Using the selected covariates, parametric survival model
assuming different hazard functions (exponential, Weibull, and log-logistic) were 
constructed. The model yielding the lowest objective function value was selected as 
the final PPS prediction model.
D. Model Evaluation
Model fit was first assessed using basic goodness of fit plots. Then, model 
evaluation was done based on objective function values (OFVs) and estimated 
standard errors of model parameters. The final model was evaluated using a visual 
predictive check (VPC) of tumor size observations and posterior predictive checks 
using DoR, PFS, and PPS. 
Relative bias and relative squared error were calculated, as defined below, for 
training and test datasets, where Obs denotes the observed value in test dataset and 
Pred denotes the predicted Obs value obtained using the final model. 
Relative error (%) = 
        
    
× 100
Squared error = (    −     ) 
Relative squared error = (
        
    
)  × 100
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Since dosing information was not available for the validation dataset, the standard
dosing scheme that was used for the index dataset was assumed. Dosing interval 
was set to 3 weeks (=0.75 month). Full standard doses were given.
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III. RESULTS
1. Exploratory Data Analysis
A. Baseline tumor size, Ksh, and DoR
Figure 5. Baseline tumor size [mm] vs. early tumor shrinkage rate [/mo].
In figure 5, larger baseline tumor size is associated with lower Ksh. 
A simple linear regression was carried out. Since linear regression is sensitive to 
outliers, two patients with Ksh greater than 1.5 were excluded.
The fitted regression equation is as follows (  =0.16) :
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Ksh = 0.62 – 0.10 log(baseline) (HER2 = 0, 1+, 2+) … (3.1.1)
Ksh = 0.73 – 0.10 log(baseline) (HER2 = 3+) … (3.1.2)
The higher intercept of the regression equation in HER2 3+ patients suggests faster 
initial tumor shrinkage in these patients.
Figure 6. Depth of response (DoR) vs. Early shrinkage rate.
With known Ksh, we can predict DoR by fitting the following nonlinear equation to 
the observations.
DoR = 
   
     	
… (3.1.3)
Inspecting Eq. (3.1.3), DoR approaches 1 as Ksh goes to infinity. The parameter θ
is equal to the magnitude of Ksh that results in DoR of 50%. Fitting our data using 
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non-linear least squares resulted in the estimate of   = 0.51. Taking a step further, 
covariate model building was carried out.
DoR = 
   
    	(         )    	
… (3.1.4)
The only significant covariate was found to be HER2 3+ status.
The resultant regression equation is as follows:
DoR = 
   
 .  	   	(  .  	(       ))    	
… (3.1.5)
Figure 7. Predicted DoR vs. Ksh in HER2 3+ and 0/1+/2+ patients.
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Figure 8. PFS as a function of DoR.
Performing a simple linear regression of log(PFS) using DoR as a predictor variable 
yields the following equation (adjusted   =0.36) :
Log(PFS) = 1.13 + 1.51 DoR … (3.1.6)
DoR alone explains about 36% of the total variability in PFS (p = 6.38 * 10  ).
The remaining unexplained variability of 64% is likely related to non-measurable 
lesions. In our data, 30.43% of the patients were diagnosed PD based on non-
measurable lesions.
Since DoR can only be known with certainty after PD as occurred, Eq. (3.1.6) has 
very little predictive value. It should be checked whether predicted DoR using Ksh 
based on Eq. (3.1.5) yield similar results. Since Ksh can be assessed at the first 
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patient visit, PFS can be predicted by using DoR predicted using Ksh. Following 
equation shows the regression result (adjusted   =0.22).
Log(PFS) = 1.07 + 1.58 DoR … (3.1.7)
The p-value of DoR is 0.000142. The coefficient of determination    decreased 
from 0.36 to 0.22.
Using predicted Ksh based on Eq. (3.1.1) and (3.1.2), DoR can be predicted using 
Eq. (3.1.5). Obviously, the predicted DoR now consists of uncertainties emanating 
from both Ksh prediction from baseline and DoR prediction from Ksh (adjusted 
  =0.13).
Log(PFS) = 1.33 + 1.25 DoR – 0.38 Liver … (3.1.8)
The uncertainty introduced by using predicted Ksh to predict DoR is partly 
compensated by using the information of liver metastasis. Whichever version of 
DoR is used, the estimates of the DoR coefficient are quite similar. The p-values of 
DoR and liver metastasis are 0.0287 and 0.0485, respectively and adjusted    is 
now 0.13. 87% of the variability in PFS remains unexplained.
The results of Cox-proportional hazard models are discussed.
Using observed DoR, logrank test resulted in p value of 5.71e-07. The relative risk 
of PD decreases by 3% with each 1% increase in DoR. The p-value of the estimated 
coefficient if 1.01e-06. 
Covariate model building resulted in ECOG score, liver metastasis, and signet-ring 
cell histology being selected.
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Table 2. Significant covariates affecting PFS using observed DoR
Covariates Relative risk Significance (p-value)
Depth of response 0.96 (per 1% increase) 2.03e-08 ***
ECOG=2 6.58 (relative to ECOG=0) 0.0004 ***
ECOG=3 10.18 (relative to 
ECOG=0)
0.047 *
Histologic grade =4 
(Signet ring cell type)
12.10 (relative to well-
differentiated histologic 
type)
0.0025 **
Liver metastasis 2.34 0.015 *
Age 1.03 (per 1 year increase) 0.045 *
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05
Each 1% increase in DoR was associated with 3.8% decrease in relative risk. 
Relative to ECOG score of 0, ECOG=1 was associated with increase in relative risk 
by 83% (p=0.064), ECOG=2 by 557.73% (p=0.0004), and ECOG=3 by 917.67% 
(p=0.047). Signet ring cell histology increased relative risk by 1110.06% relative to 
well-differentiated histologic type (p=0.0025). Presence of liver metastasis resulted 
in increase of relative risk by 134.48% (p=0.015). Increase of age by 1 year resulted 
in an increased relative risk by 3.02%. The logrank test resulted in p value of 
4.352e-08.
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Table 3. Significant covariates affecting PFS using predicted DoR using observed 
Ksh
Covariates Relative risk Significance (p-value)
Depth of response 
(predicted)
0.97 (per 1% increase) 0.00041 ***
ECOG=1 1.97 (relative to ECOG=0) 0.037 *
ECOG=2 3.85 (relative to ECOG=0) 0.0087 **
Histologic grade =4 
(Signet ring cell type)
6.18 (relative to well-
differentiated histologic 
type)
0.02 *
Liver metastasis 2.15 0.02 *
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05
Age was not a significant covariate when predicted DoR was used.
In all cases, DoR seem to be a significant predictor of PFS. If we could increase 
DoR by 1%, we can theoretically reduce risk of PD by about 3%.
Shown below is a table of correlation coefficients of baseline tumor size (i.e. target 
lesion sum) with metastatic organs.
Table 4. Metastatic status and baseline tumor size
Organ involved Correlation coefficient with baseline
Liver (solid organ) 0.24
Lung (solid organ) 0.26
Ovary (solid organ) 0.25
Distant lymph nodes -0.011
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Peritoneum (unmeasurable) -0.022
Bone infiltration (unmeasurable) 0.026
Assessment of trastuzumab effect stratified by HER2 receptor status is shown in the 
following table.
Table 5. Response rate (RR), depth of response (DOR) and PFS stratified by 
trastuzumab treatment and HER2 receptor status
HER2 0/1+/2+ HER2 3+
No Trastuzumab RR 25% (1/4) 57.14% (4/7)
DOR 26.12% ± 20.73% 40.75% ± 19.10%
PFS 225 days (median)
197 days (mean)
151 days (median)
141 days (mean)
Trastuzumab RR 50% (8/16) 78.57% (33/42)
DOR 29.02% ± 19.18% 54.88% ± 28.34%
PFS 153 days (median)
184 days (mean)
246 days (median)
314 days (mean)
Interestingly, RR and DOR were higher in HER2 3+ patients compared to HER2 
0/1+/2+ patients in the no trastuzumab group despite shorter PFS. However, this 
difference was not statistically significant.
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B. Distribution of DoR
Figure 9. Histogram with kernel density estimates of DoR overlaid.
Figure 9 shows the empirical distribution of observed DoR in our data. There is 
suggestion of multi-modality in the distribution. 
Based on the above, DoR was clustered into four groups – 1: non-responder, 2: 
partial responder (low), 3: partial responder (high), and 4: complete responder. 
Division into these four clusters was implemented using K-means clustering 
algorithm.
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Figure 10. K-means clustering of (Ksh, DoR).
Decision tree classification was performed using R package ‘rpart’ to identify 
predictors of the above clusters. (1: Complete Response, 2: Partial Response (High), 
3: Partial Response (Low), 4: No Response)
The final tree after pruning resulted in the following:
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Figure 11. Pruned decision tree diagram to predict DoR class.
The only significant factor determining the response is log(baseline). The resultant
probability masses of Node 2 and 3 are nearly mirror images of each other. 
2. Tumor Size Model
The parameter estimates of the final tumor size model are summarized in Table 6.
Table 6. Estimation result of tumor size model
Parameter Estimate RSE (%)
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Coefficient of drug efficacy (    )
Cytotoxic drugs + Immune surveillance
Trastuzumab
17.29
1.78
32.18
18.32
Rate of tumor progression ( )
Well differentiated
Moderately differentiated
Poorly differentiated
Signet ring cell
0
0.084 
0.15 
0.37 
-
33.55
25.78
17.99
Fraction of tumor cells resistant to 
Cisplatin/Capecitabine/5-FU   (P)
Trastuzumab   (Q)
HER2-H
HER2-L
8.50 (0.89)
1.59 (0.61)
2.27 (0.69)
27.67
24.53
42.89
KDE (/month) 0.81 27.22
Maximum tumor size (    ) (mm) 71.46∙log(base) 0.17
Intercept of initial SGR -0.14 9.27
Slope of initial SGR
HER2-H
HER2-L
0.03
0.051
13.32
20.73
Inter-individual Variability
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      _       	   (CV%) 64.64 15.04
  (CV%) 119.2 21.44
  , 	(CV%) 158.8 13.27
Residual error 
 Additive 2.62 12.96
(     : Cell kill coefficient, β: Coefficient of tumor progression rate,     : 
Maximum tumor size)
HER2 3+ status was associated with larger spread of trastuzumab and cisplatin/5-
FU resistance probabilities. 
Figure 12. Distribution of post-hoc trastuzumab resistance probability.
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Figure 13. Distribution of post-hoc 5-FU resistance (=cisplatin resistance) 
probability.
3. Survival Model
A. PFS prediction model
Log-logistic hazard model provided the best fit to describing the hazard of 
appearance of new lesion or progression of target lesions. The estimate of this 
hazard was 0.099/month. Prior gastrectomy history and ECOG score were found as
significant covariates.
Following is a table showing the estimation result of the Model 2.
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Table 7. Estimation results of Model 2
Covariate Estimate (RSE%) Relative Risk (p-value)
PFS based on non-measurable lesions
Baseline hazard (mo-1) 0.099 (27.98) -
Shape parameter 2.07 (25.23) -
Prior gastrectomy -1.89 (23.6) 0.15 (0.00013)
ECOG score 0.87 (38.46) 0.87 (0.014)
B. PPS prediction model
PFS was found to be a significant predictor of PPS when histologic grade is well- or 
moderately differentiated. Age was marginally significant.
Log-logistic hazard model seemed to best fit our data. Predicted PFS of Eq. (3.1.8) 
was used as a covariate. When histologic grade is either poorly differentiated or 
signet ring cell, it seems that PFS has no effect on patient outcome. When histologic 
grade is either well- or moderately differentiated, longer PFS and smaller baseline 
tumor size are associated with a lower hazard. 
Table 8. Estimation results of PPS prediction model
Covariate Estimate (RSE%) Relative Risk (p-value)
Post-progression survival model
Baseline hazard (mo-1) 0.17 (22.98) -
Shape parameter 0.78 (30.55) -
Length of PFS (month) -0.0623 (41.87) 0.94 (0.0066)
Tumor size at last 
assessment (1 SDa)
0.35 (32.87) 1.42 (0.038)
a standard deviation
43
4. Model Evaluation
A. Goodness of fit plots of the tumor size model
Following is a mirror plot showing observed and predicted tumor sizes.
Figure 14. Mirror plots of the tumor size model.
The tumor size model seems sufficiently flexible to fit the observed tumor sizes 
with appropriate choice of random effects. Following are goodness of fit plots.
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Figure 15. Basic goodness of fit plots of the tumor size model.
B. Validation
Following are VPCs of tumor size model generated on index and validation datasets, 
respectively.
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Figure 16. VPC of the tumor size model using the index dataset (n=1,000).
Figure 17. VPC of the tumor size model using the validation dataset (n=1,000).
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Figure 18. Simulated (red) and observed (blue) KM survival curves of PFS using 
training data (n=1,000).
Figure 19. Validation of PFS prediction using test data (n=1,000)
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Figure 20. Simulated (red) and observed (blue) KM survival curves of PPS using 
training data (n=1,000).
Figure 21. Validation of PPS prediction using test data (n=1,000).
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Kaplan Meier survival curves were overlaid with the observed survival curve of the 
index and validation datasets.
Censoring distribution was used to generate censored time events. The simulated 
curves coincide well with the observed curves, although there is a slight tendency to 
underestimate PFS in the early period (<10 months).
In conclusion, our models seem to generalize well to unseen data in terms of 
predicting PFS and PPS.
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IV. DISCUSSION
1. Data
There are significant differences of baseline SLD, HER2 receptor status, and 
proportions of patients with previous gastrectomy between training and test datasets 
(see Table 1). 
The main cause of the difference in SLD between the two datasets is likely due to 
using different versions of RECIST in assessing sum of tumor diameters of the 
target lesion46. RECIST 1.0 was used for the training dataset while RECIST 1.1 was 
used for the test dataset, which was prepared in the final stage of analysis. 
As for the difference in the proportions of HER2 receptor status, this is a result of 
deliberately enriching the test dataset with HER2 negative patients to see whether 
the model generalizes well to these patients. 
2. Tumor size model (Model 1)
Key findings based on the estimation results of Model 1 are as follows. 
1) HER2 receptor status is crucial in predicting response to trastuzumab. Our 
results suggest that higher HER2 receptor density is associated with lower 
probability of trastuzumab resistance.
2) Higher histologic grade is associated with faster tumor progression.
3) Larger tumor is associated with faster tumor progression.
Model validation using visual predictive check and relative bias estimates suggest 
that our model generates reliable predictions for external, unforeseen observations.
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3. Survival Model
A. PFS prediction model
1) PFS prediction model
Risk factors that lead to higher probability of non-target lesion progression - ECOG 
score and previous gastrectomy status - were successfully identified. Baseline 
hazard was best described using log-logistic distribution and suggests that the 
hazard initially increases and then decreases.
The cause of prior gastrectomy being associated with a lower probability of non-
target lesion progression is unclear. It is possible that this is due to lower 
trastuzumab clearance in patients with prior gastrectomy 14. 
B. PPS prediction model
The estimated parameters shown in Table 3 suggest the following:
(1) Mortality is greatest immediately after PD diagnosis and decreases
thereafter.
(2) Longer PFS and smaller tumor size at last assessment are associated with a 
survival benefit when WHO histologic grade is I or II (i.e. well-
differentiated or moderately differentiated). With higher histologic grades, 
survival does not seem to be affected by these factors.
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V. CONCLUSION
This work successfully characterized dose-response relationship and important 
covariates affecting treatment response under the KPD modeling framework. The 
developed model was successfully validated using an out-of-sample dataset. Based 
on the model, it is possible to generate individualized predictions of treatment 
response and patient survival. This will help optimize treatment in HER2 positive 
metastatic gastric cancer patients.
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ABSTRACT (IN KOREAN)
HER2 양성 전이성 위암 환자의 Trastuzumab 치료반응 예측모델
<지도교수 박 경 수>
연세대학교 대학원 의과학과
채동우
목적
본 연구는 HER2 양성 전이성 위암 환자에서 포괄적 치료 반응 예측
모델을 수립하기 위하여 수행되었다.
방법
데이터는 세브란스 병원에서 수행된 ToGA 임상 시험에 참여한 69 명의
진행성 위암 환자로부터 얻어졌다. 각 방문 시마다 RECIST 평가가
이루어졌고 종양 크기는 최장축의 합(SLD)으로 측정하였다. 종양 크기
예측 모델, 비측정 병변의 PD 예측 모델, 그리고 PPS 예측 모델을
순차적으로 개발하여 환자의 치료 반응을 포괄적으로 기술하였다. 86 명의
환자로 이루어진 별도의 데이터를 이용하여 모델 검증을 수행하였다.
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결과
개발된 TGI 모델에 의해 생성된 종양 크기 예측치는 관측치와 좋은
적합을 보였다. HER2 3+ 환자들이 HER2 1+/2+ 환자에 비하여
trastuzumab 에 대한 높은 감수성을 보였다. 높은 WHO 조직학적 등급은
빠른 종양 진행과 연관되었다. 위절제 수술 과거력과 낮은 ECOG 점수는
비측정 병변의 PD 에 대한 낮은 hazard 와 연관되었다. PFS 와 PPS 는
WHO 조직학적 등급이 I 또는 II 일 때 양성 상관을 보였다. 이러한
상관성은 WHO 조직학적 등급 III 과 IV 에서는 나타나지 않았다.
결론
개발된 모델에 근거하여 개인별 치료 반응과 생존을 예측하는 것이
가능할 것으로 생각된다. 이는 HER2 양성 전이성 위암 환자에서 치료를
최적화시키는데 도움이 될 것이다.
